Spots Global Cancer Trial Database for Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer
Official Title: Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study
Study ID: NCT06243432
Conditions
Interventions
Study Description
Brief Summary: CYCLHER is a retrospective observational multicentric italian study aimed to evaluate the correlation between hormone receptors (HR) and HER2 immunohistochemistry (IHC) levels and treatment'response in patients affected by advanced breast cancer treated with first line CDK4/6 inhibitor plus endocrine therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fondazione Policlinico A. Gemelli - IRCCS, Rome, , Italy
Contact Details
Name: Alessandra Fabi, MD
Affiliation: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
